coronary artery disease

Oxidized Phospholipid PGPC Impedes Angiogenesis by Disrupting Endothelial Autophagy via NPC1-Mediated Syntaxin 17 Modification

By MedXY 10/10/2026

The oxidized phospholipid PGPC inhibits angiogenesis in ischemic heart disease by impairing endothelial autophagic flux through NPC1-induced acetylation and ubiquitination of syntaxin 17, unveiling new potential therapeutic targets for coronary artery disease.

Cardiology Clinical Updates news

Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials: A Genotype-First Precision Prevention Approach

By MedXY 09/15/2026

This review synthesizes emerging evidence from the PROACT trials on genotype-first identification of subclinical coronary atherosclerosis using polygenic risk scores (PRS), highlighting feasibility, engagement, and high prevalence of silent plaque with implications for targeted early intervention.

Cardiology news Public Health

Linking Air Pollution to Heart Health: Chronic PM2.5 Exposure and Coronary Endothelial Dysfunction

By MedXY 09/11/2026

Chronic exposure to fine particulate matter (PM2.5) is linked to epicardial coronary endothelial dysfunction, an early marker of coronary artery disease, as demonstrated by invasive coronary vasoreactivity testing.

Cardiology news

Long-Term Benefits of Quantitative Flow Ratio-Guided PCI: Insights from the 5-Year FAVOR III China Trial

By MedXY 09/11/2026

The FAVOR III China trial demonstrates that QFR-guided percutaneous coronary intervention significantly reduces major adverse cardiac events over 5 years, mainly by decreasing myocardial infarction and ischemia-driven revascularization compared to angiographic guidance.

Cardiology Diabetes & Endocrinology news

suPAR as a Novel Marker for Residual Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes with Coronary Artery Disease

By MedXY 08/21/2026

In type 2 diabetes patients with coronary artery disease, suPAR levels remain unchanged despite treatment and independently predict adverse cardiovascular events beyond hs-CRP, highlighting suPAR's potential in identifying treatment-resistant inflammation and refining cardiovascular risk stratification.

Cardiology Clinical Updates Gastroenterology news

Gut Microbiota-Derived Imidazole Propionate as a Predictor of Cardiometabolic Risk in Coronary Artery Disease: Evidence and Clinical Implications

By MedXY 08/18/2026

Emerging evidence identifies circulating imidazole propionate, a gut microbiota-derived metabolite, as an independent predictor of major adverse cardiovascular events in patients with coronary artery disease, offering novel insights into personalized risk stratification and therapeutic targets.

Cardiology Diabetes & Endocrinology news

Ultra-Thin Sirolimus-Eluting Stents Show Noninferiority to Everolimus-Eluting Stents in Diabetic Multivessel CAD: Insights from TUXEDO-2 Trial

By MedXY 07/02/2026

The TUXEDO-2 trial demonstrated that ultra-thin strut biodegradable polymer sirolimus-eluting stents are noninferior to durable polymer everolimus-eluting stents in diabetic patients with multivessel coronary artery disease at 1-year follow-up.

Cardiology news

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank

By MedXY 06/27/2026

Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment and prevention strategies.

Cardiology news

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

By MedXY 06/10/2026

ORBITA-FIRE shows that angina occurs at much lower, individualized FFR and RFR thresholds than standard ischemia cutoffs, and these thresholds rise with exercise intensity.

Cardiology news

Great Debate: Is the New Risk Factor-Weighted Clinical Likelihood Model Useful for Estimating Pre-Test Probability of Obstructive Coronary Artery Disease?

By MedXY 06/10/2026

The RF-CL model is a new ESC-recommended tool for estimating the pre-test probability of obstructive CAD in suspected chronic coronary syndromes. It improves risk stratification and may reduce unnecessary testing, though symptom interpretation and practical limits remain debated.

Cardiology Diabetes & Endocrinology news

Waist-to-Height Ratio Is Linked to Coronary Artery Disease Risk in Type 1 Diabetes: 19-Year Study

By MedXY 06/07/2026

A 19-year Finnish cohort study found that a higher waist-to-height ratio was linked to increased coronary artery disease risk in type 1 diabetes, especially in people without albuminuria.

Cardiology news OB/GYN & Women’s Health

Women with Chronic Coronary Artery Disease: Long-Term Outcomes After PCI vs CABG

By MedXY 05/26/2026

In women with chronic severe coronary artery disease, CABG was linked to lower long-term rates of death, stroke, heart attack, repeat revascularization, and cardiovascular readmission than PCI.

Cardiology news

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial

By MedXY 05/19/2026

In patients with prior PCI but no prior MI, evolocumab significantly lowered LDL-C and reduced major cardiovascular events, including myocardial infarction and urgent revascularization, supporting intensive lipid lowering after coronary intervention.

Cardiology news

Focal vs. Diffuse Coronary Artery Disease: How Disease Pattern Influences PCI’s Placebo-Controlled Symptom Relief in ORBITA-2

By MedXY 04/22/2026

ORBITA-2 reveals PCI’s superior placebo-controlled angina relief in focal vs. diffuse coronary artery disease, with physiological disease patterns guiding treatment decisions.

Cardiology Clinical Updates Diabetes & Endocrinology news

Precision Phenotyping in Cardiometabolic Medicine: Genetic Susceptibility of Diabetes Subtypes and Coronary Artery Disease Risk

By MedXY 04/01/2026

This review synthesizes evidence on the genetic architecture of adult-onset diabetes subtypes, highlighting that Moderate Obesity-related Diabetes (MOD) is uniquely and causally linked to coronary artery disease risk through polygenic and Mendelian randomization analyses.

Cardiology Diabetes & Endocrinology news

Chronic Inflammation via suPAR: The Missing Link Between Diabetes and Cardiovascular Mortality

By MedXY 03/15/2026

A landmark study in Diabetes Care reveals that soluble urokinase plasminogen activator receptor (suPAR) mediates over half of the increased risk for adverse cardiovascular outcomes in patients with diabetes and coronary artery disease, surpassing traditional inflammatory markers like hs-CRP.

Cardiology Clinical Updates news

Beyond Stenosis: The Prognostic Impact of Quantitative Plaque Volumetrics in Early Coronary Artery Disease

By MedXY 03/11/2026

This review synthesizes findings from a PROMISE trial substudy, revealing that quantitative coronary plaque volume and burden are independent predictors of MACE in symptomatic outpatients, even when total plaque levels are low.

Clinical Updates news

Beyond Traditional Risk Factors: Deconstructing the Burden of Coronary Atherosclerosis in Liver Transplant Recipients

By MedXY 03/07/2026

A landmark nationwide study reveals that liver transplant recipients face significantly higher prevalence and severity of coronary atherosclerosis and high-risk plaque compared to matched controls, independent of traditional cardiovascular risk factors.

Cardiology Clinical Updates news

Percutaneous Coronary Intervention Before TAVR: A Nationwide Synthesis of Clinical Outcomes and Bleeding Risks

By MedXY 02/28/2026

A nationwide Swedish registry analysis demonstrates that routine PCI before TAVR for significant coronary artery disease does not improve survival or reduce urgent revascularization, but significantly increases bleeding risk while reducing future nonurgent procedures.

Cardiology Clinical Updates news

Sex-Specific Risk Thresholds in Coronary Artery Disease: Why Plaque Burden Metrics Demand Re-evaluation in Women

By MedXY 02/28/2026

A secondary analysis of the PROMISE trial reveals that women face elevated cardiovascular risk at significantly lower coronary plaque thresholds than men, necessitating a paradigm shift toward sex-stratified interpretation of coronary CT angiography.